Category Archives: Pradaxa

Subscribe to Pradaxa RSS Feed

Boehringer Ingelheim Sanctioned Again in Pradaxa Litigation

Posted in Pradaxa

As we have previously reported, Boehringer Ingelheim, the manufacturer of Pradaxa, has been sanctioned during the course of the federal litigation for destroying relevant documents. In a recent Case Management Order, Judge David R. Herndon, Chief Judge United States District Court, presiding over the litigation, revisited the manufacturer’s misconduct and fixed new sanctions. In the… Continue Reading

First Two Bellwether Trials in Pradaxa Litigation Scheduled

Posted in Pradaxa

The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated… Continue Reading

Court Orders Boehringer Ingelheim to Unseal Confidential Documents

Posted in Pradaxa

The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated… Continue Reading

FDA Announces New Safety Assessment for Pradaxa

Posted in Pradaxa

The dangers associated with Pradaxa use are well known. Since reaching the United States’ market in 2010, Pradaxa has been linked to hundreds of deaths. The Food and Drug Administration (FDA) has received numerous adverse event reports for injuries and complications from Pradaxa use. Physicians and analysts have commented that the health risks associated with… Continue Reading

Boehringer Ingelheim Sanctioned $931,000 for Destroying Documents

Posted in Pradaxa

The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated… Continue Reading

Court to Select Bellwether Cases in Pradaxa Federal MDL

Posted in Pradaxa

As we have previously reported, the use of Pradaxa has been linked to serious injury.  There are nearly 600 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant.  Unfortunately, there is no readily-available antidote for the internal bleeding… Continue Reading

Warning Added to Pradaxa for Blood Condition

Posted in Defective Drugs, Pradaxa

As we have previously reported, the use of Pradaxa has been linked to serious injury.  There are nearly 600 cases currently pending in federal court.  The lawsuits allege that Pradaxa, manufactured by Boehringer Ingelheim, Inc., has resulted in devastating and sometimes fatal outcomes.  Pradaxa is a blood thinner that was marketed to replace warfarin, a… Continue Reading

Pradaxa Manufacturer Ordered to Produce Employee Records

Posted in Defective Drugs, Pradaxa

As we have previously reported, the use of Pradaxa has been linked to serious injury.  There are nearly 600 cases currently pending in federal court.  The lawsuits allege that Pradaxa, manufactured by Boehringer Ingelheim, Inc., has resulted in devastating and sometimes fatal outcomes.  Pradaxa is a blood thinner that was marketed to replace warfarin, a… Continue Reading

Pradaxa Lawsuits Move Closer to Trial

Posted in Defective Drugs, Pradaxa

As we have previously reported, the use of Pradaxa has been linked to serious injury.  There are nearly 600 lawsuits pending in federal court.  The Multi District Litigation (MDL), centralized in a Chicago federal court, continues to move forward.  The next Status Conference in the Pradaxa litigation has been schedule for the middle of May…. Continue Reading

The Number of Pradaxa Injuries Continue to Climb

Posted in Pradaxa

Pradaxa stormed the market in 2010 and was widely prescribed as an anticoagulant drug used to prevent or treat blood clots.  Initially, it seemed effective at reducing the risk of stroke, particularly in patients with atrial fibrillation. The manufacturer, German-based Boehringer Ingelheim Pharmaceuticals, Inc., has realized more than $ 1 billion in sales from the… Continue Reading

New Study Shows Pradaxa More Dangerous Than Previously Believed

Posted in Pradaxa

As, we have previously reported, the number of Pradaxa lawsuits continues to grow across the country.  The number of lawsuits has increased by nearly 17% in recent months and now approaches 200 nationwide. The medication resource center, DrugRisk, continues to receive, organize and disseminate safety issues relating to Pradaxa.  New reports indicate Pradaxa is more… Continue Reading

Pradaxa Litigation Continues to Grow

Posted in Pradaxa

The number of Pradaxa lawsuits continues to grow across the country. According to recent reports, there are currently 176 cases pending in federal court with more expected to follow. Unfortunately, individuals continue to experience negative effects from the drug including uncontrollable bleeding. Unlike its competitor Coumadin, known generically as Warfarin, developers were unable to create… Continue Reading

Patients Taking Pradaxa at 33% Higher Risk

Posted in Pradaxa

According to recent reports, patients that are taking the anti-clotting drug Pradaxa have a 33% higher risk of heart attack or severe symptoms of heart disease than patients taking Warfarin. The finding, from Cleveland Clinic researchers Ken Uchino, MD, and Adrian V. Hernandez, MD, PhD, is based on data from seven clinical trials that enrolled… Continue Reading

Pradaxa Litigation Given MDL Status

Posted in Defective Drugs, Pradaxa

The blood thinner mediation Pradaxa is generally prescribed to prevent strokes among patients with irregular heartbeats. In September 2011, the drug became the subject of an investigation in New Zealand after as many as five elderly Pradaxa patients reportedly died as a result of internal bleeding/ hemorrhaging. Another 36 Pradaxa patients reportedly suffered bouts of… Continue Reading

Pradaxa Complaints Increase Despite FDA Approval

Posted in Defective Drugs, Pradaxa

Pradaxa (dabigatran etexilate mesylate) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in October 2010, to prevent strokes among patients with atrial fibrillation (irregular heartbeat). In the last quarter of 2010 alone, the FDA received over 300 complaints about the side effects of Pradaxa. In November 2011, Boehringer,… Continue Reading

Pradaxa Side Effects to Watch For

Posted in Defective Drugs, Pradaxa

The FDA-approved blood thinner mediation Pradaxa is quickly becoming one of the leading stroke prevention therapies in the atrial fibrillation drug market. However, it has been reported that the risk of internal bleeding associated with Pradaxa is five (5) times higher than originally estimated. Some symptoms of Pradaxa side effects include lethargy, unusual bruising or… Continue Reading